-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The biopharmaceutical industry is one of the key strategic emerging industries in China.
At present, in addition to the state is introducing a series of favorable policies to support the development of the industry, many places are also further promoting the high-quality development of the biopharmaceutical industry
.
It is understood that since this year, many places have put forward new plans for the future development of their respective biomedical industries
.
For example, in recent days, in order to promote the open innovation of the entire biomedical industry chain and build a nationally influential biomedical industry cluster, Jiangsu Province specially issued the "Policies and Measures for Promoting the High-quality Development of the Province’s Biomedical Industry" ( Hereinafter referred to as "Several Policy Measures")
.
Specifically, the "Several Policy Measures" will propose 30 policy measures from 7 aspects including industrial development goals, product development, review and approval, manufacturing, application and promotion, talent recruitment, and industrial ecology, forming a comprehensive industry chain.
"Policy package"
.
It is understood that in recent years, Jiangsu Province has already included the biomedicine industry as a strategic emerging industry and 13 advanced manufacturing clusters, which has promoted the rapid and healthy development of the biomedical industry
.
From the current point of view, the development of the biomedical industry in Jiangsu Province has achieved remarkable results.
In 2020, the output value of the biomedical industry in Jiangsu Province will account for about 1/6 of the country; and in the first half of this year, the output value of the biomedical industry in Jiangsu has increased year-on-year.
16.
4%
.
Therefore, for the "Several Policy Measures" issued by Jiangsu Province this time, the industry generally believes that the province's biomedical industry chain supply chain will be improved and strengthened, and the high-quality development of Jiangsu's biomedical industry will be promoted to a new level
.
In addition to Jiangsu Province, the Hainan Provincial Food and Drug Administration has also issued the "Notice on Further Optimizing Services to Support the High-Quality Development of the Biopharmaceutical Industry", and introduced a total of 12 optimization service measures, from promoting the development of industrial clusters and encouraging the undertaking of the production of pharmaceuticals and medical devices.
Transferring, facilitating registration, testing and clinical evaluation, and optimizing the review and approval of 4 aspects, continuously optimize the business environment, and support the high-quality development of Hainan's biomedical industry
.
In addition, on September 23, at a high-quality forum, the relevant person in charge of Zhuhai District revealed that Zhuhai High-tech Zone will issue a series of supporting policies such as a five-year action plan and special policies to promote the development of the biomedical industry to promote the biomedical industry.
Gather
.
Subsequently, at the subsequent press conference of the "2021 Shanghai International Biomedical Industry Week", the relevant person in charge of the Shanghai Drug Administration also made it clear that Shanghai will speed up the establishment of innovative medical devices in Shanghai, and fully promote the high-quality development of the biomedical industry
.
In general, with the vigorous development of the global biomedical industry, China's biomedical industry is accelerating its rise
.
In this context, the market size of China's biomedical industry is expected to exceed 500 billion yuan by 2026
.
The industry predicts that the future huge market prospects, a good external environment, a solid industrial foundation, and strong innovation capabilities will continue to provide assistance for the high-quality development of the domestic biomedical industry
.
At present, in addition to the state is introducing a series of favorable policies to support the development of the industry, many places are also further promoting the high-quality development of the biopharmaceutical industry
.
It is understood that since this year, many places have put forward new plans for the future development of their respective biomedical industries
.
For example, in recent days, in order to promote the open innovation of the entire biomedical industry chain and build a nationally influential biomedical industry cluster, Jiangsu Province specially issued the "Policies and Measures for Promoting the High-quality Development of the Province’s Biomedical Industry" ( Hereinafter referred to as "Several Policy Measures")
.
Specifically, the "Several Policy Measures" will propose 30 policy measures from 7 aspects including industrial development goals, product development, review and approval, manufacturing, application and promotion, talent recruitment, and industrial ecology, forming a comprehensive industry chain.
"Policy package"
.
It is understood that in recent years, Jiangsu Province has already included the biomedicine industry as a strategic emerging industry and 13 advanced manufacturing clusters, which has promoted the rapid and healthy development of the biomedical industry
.
From the current point of view, the development of the biomedical industry in Jiangsu Province has achieved remarkable results.
In 2020, the output value of the biomedical industry in Jiangsu Province will account for about 1/6 of the country; and in the first half of this year, the output value of the biomedical industry in Jiangsu has increased year-on-year.
16.
4%
.
Therefore, for the "Several Policy Measures" issued by Jiangsu Province this time, the industry generally believes that the province's biomedical industry chain supply chain will be improved and strengthened, and the high-quality development of Jiangsu's biomedical industry will be promoted to a new level
.
In addition to Jiangsu Province, the Hainan Provincial Food and Drug Administration has also issued the "Notice on Further Optimizing Services to Support the High-Quality Development of the Biopharmaceutical Industry", and introduced a total of 12 optimization service measures, from promoting the development of industrial clusters and encouraging the undertaking of the production of pharmaceuticals and medical devices.
Transferring, facilitating registration, testing and clinical evaluation, and optimizing the review and approval of 4 aspects, continuously optimize the business environment, and support the high-quality development of Hainan's biomedical industry
.
In addition, on September 23, at a high-quality forum, the relevant person in charge of Zhuhai District revealed that Zhuhai High-tech Zone will issue a series of supporting policies such as a five-year action plan and special policies to promote the development of the biomedical industry to promote the biomedical industry.
Gather
.
Subsequently, at the subsequent press conference of the "2021 Shanghai International Biomedical Industry Week", the relevant person in charge of the Shanghai Drug Administration also made it clear that Shanghai will speed up the establishment of innovative medical devices in Shanghai, and fully promote the high-quality development of the biomedical industry
.
In general, with the vigorous development of the global biomedical industry, China's biomedical industry is accelerating its rise
.
In this context, the market size of China's biomedical industry is expected to exceed 500 billion yuan by 2026
.
The industry predicts that the future huge market prospects, a good external environment, a solid industrial foundation, and strong innovation capabilities will continue to provide assistance for the high-quality development of the domestic biomedical industry
.
